1
Total deals
$127.0M
Total value
$127.0M
Avg deal
$127.0M
Largest
| # | Acquired | Date | Type | Status | Price | |
|---|---|---|---|---|---|---|
| 1 |
K
Kezar Life Sciences-Preclinical Assets
Preclinical Assets focus on small-molecule inhibitors targeting the Sec61 transl…
|
2026-03-12 | Acquisition | Complete | $127.0M | Deal → |